Navigation Links
DSM Expands its Innovative Biomanufacturing Technology Portfolio With the Introduction of the New Kremer Method™
Date:6/27/2011

PARSIPPANY, N.J., June 28, 2011 /PRNewswire/ -- Royal DSM, the global Life Sciences and Materials Sciences company, today announced the introduction of the Kremer Method™, an innovative proprietary technology developed by DSM scientists which improves downstream processing of monoclonal antibodies (mAbs) for faster and more cost effective production of biopharmaceuticals.  The Kremer Method™ reduces processing and preparation times, labor and materials requirements and cost of goods for a more sustainable manufacturing platform.

DSM provides and develops technologies for optimizing mammalian cell culture processes. Examples are the proprietary XD® Technology for use with mammalian cell lines. The XD® process creates very high cell densities within the bioreactor, resulting in significant output enhancements of 5-15 fold using commercially available equipment.  In the downstream processing area, DSM's proprietary Rhobust® technology is the next generation in expanded bed chromatography (EBA), using cross linked agarose beads with Tungsten Carbide to increase the particle density. Rhobust® is applied as a direct capture and clarification step for mammalian and microbial harvest to increase yields, reduce the number of unit operations and reduce process cost.  The new Kremer Method™ further optimizes the downstream processing of proteins and monoclonal antibodies.

Karen King, President of DSM Biologics, a business unit of DSM Pharmaceutical Products, commented: "DSM is continually innovating to advance the world of biopharmaceutical manufacturing to the next level.  We are pleased to announce the introduction of the new DSP optimization technology, the Kremer Method™.  The combination of the Kremer Method™ with our other proprietary technologies significantly reduces the overall costs and processing times of biopharmaceuticals while maintaining high product quality."

Rolf Douwenga, Vice President of Global R&D for DSM Biologics explained: "The Kremer Method™ is a valuable addition to the platform of DSM's technologies addressing the full range of mammalian cell culture systems for protein and monoclonal antibody production. The method uses in-line dilution to streamline the purification and polishing of mAbs into one single continuous step in a flow-through mode. This eliminates the need for storage and reduces the amount of material usage such as buffers and resins. The Kremer Method™ reduces processing and preparation times, labor requirements and the cost of goods and presents an ideal solution to achieving cost effective processing."

After the capture step in conventional downstream processes, further purification and polishing of proteins are traditionally carried out as two separate batch unit operations. With the Kremer Method™ these steps are streamlined to work as one single unit operation.  Using this method; Host Cell Proteins (HCP's) were removed to a level below the limits of detection; complete aggregate removal was observed comparable to current state of the art processes; and recoveries of 90% were achieved. Several patent applications have already been filed.

XD® is a registered trademark of DSM

Rhobust® is a registered trademark of DSM

DSM – Bright Science. Brighter Living.™ DSM Pharmaceutical Products is a Business Group of Royal DSM N.V., a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about euro 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsmbiologics.com and www.dsm.com.For more information:Karen King

Rolf DouwengaPresident, DSM Biologics

Vice President of Global R&D, DSM Biologics+1 973 257 8220

Tel: +1 973 257 8220karen.king@dsm.com  

rolf.douwenga@dsm.com Forward-looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.


'/>"/>

SOURCE DSM
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... YORK , March 24, 2017 ... ... a leading publisher of cannabis market research, the legal cannabis ... percent CAGR through 2021, despite conflicting signals from the current ... points out that the two biggest drivers of growth in ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 ... market of deep learning solutions within the healthcare domain. Primarily driven ... a novel solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... -- Today Stock-Callers.com have issued research reports on ... (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences Corp. (NYSE: ... These companies are part of the Healthcare sector, which gave ... rd , 2017, with the NYSE Health Care Index declining ... in the S&P 500 were down about 0.4% as a ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association (RBMA) ... annual awards, now in their 12th year, are among the most prestigious in radiology ... 2016, the awards were retooled to recognize achievements in both large budget (over $5,000) ...
(Date:3/24/2017)... Arizona (PRWEB) , ... March 24, 2017 , ... ... Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during the ...
(Date:3/24/2017)... ... ... The law firm of Enea, Scanlan & Sirignano, LLP, with ... C. Enea has joined the firm as an associate attorney. Ms. Enea, who previously ... law, Medicaid planning and applications, and Wills, Trusts and Estates. Samantha A. Lyons, ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through Social ... devotional journal chronicling the writer’s path toward true communion with God. “Finding Christ ... #TruthwithGrace” is the creation of published author Lea Michelle Johnson, a follower of ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health Organization ... could be four million Zika-related cases in the Americas within the next year. Lyme ... cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other ...
Breaking Medicine News(10 mins):